Výsledky vyhledávání - "Shugufta Khan"

Data from HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1

Autor: Xiaoting Zhang, Elyse E. Lower, Jiang Wang, Shugufta Khan, Charif Mahmoud, Dan Zhao, Yijuan Zhang, Marissa Leonard, Yongguang Yang

Studies of the estrogen receptor (ER) coactivator protein Mediator subunit 1 (MED1) have revealed its specific roles in pubertal mammary gland development and potential contributions to breast tumorigenesis, based on coamplification of MED1 and HER2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3994d725d906c9285af021e262b06035
https://doi.org/10.1158/0008-5472.c.6509763

Zobrazit plný text záznamu

Supplementary Information Figure S1 to S5 from HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1

Autor: Xiaoting Zhang, Elyse E. Lower, Jiang Wang, Shugufta Khan, Charif Mahmoud, Dan Zhao, Yijuan Zhang, Marissa Leonard, Yongguang Yang

Supplementary Information - This file contains Supplemental Procedures, Supplemental References, Supplemental Table1, Supplementary Figure Legends, and Supplementary Figures. Supplemental Procedure describes the methods and PCR primers used in this s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad1c6ca7fdf4f39333d7fb651b6c27c
https://doi.org/10.1158/0008-5472.22417173.v1

Zobrazit plný text záznamu

HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1

Autor: Marissa Leonard, Xiaoting Zhang, Charif Mahmoud, Elyse E. Lower, Dan Zhao, Yijuan Zhang, Yongguang Yang, Jiang Wang, Shugufta Khan

Publikováno v: Cancer Research. 78:422-435

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b6eda4f846d041a594f3e1426c129c0
https://doi.org/10.1158/0008-5472.can-17-1533

Zobrazit plný text záznamu

Abstract P3-05-16: The effect of HER-2/neu inhibition on prolonging clinical benefit with fulvestrant treatment for metastatic estrogen receptor positive breast cancer patients treated with trastuzumab

Autor: Xiaoting Zhang, Harriet Kumar, Mahmoud Charif, Shugufta Khan, Elyse E. Lower, Neetu Radhakrishnan, Diane Kennedy

Publikováno v: Cancer Research. 75:P3-05

Background: Fulvestrant is a well-established treatment for postmenopausal patients with estrogen receptor (ER) positive metastatic breast cancer, and some patients experience prolonged clinical benefit exceeding one year. HER2 activation is a major

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8d3195125a1d9b5fc438b170b9458089
https://doi.org/10.1158/1538-7445.sabcs14-p3-05-16

Zobrazit plný text záznamu

The effect of trastuzumab therapy on clinical benefit from fulvestrant treatment for metastatic estrogen receptor-positive breast cancer patients

Autor: Diane Kennedy, Mahmoud Charif, Neetu Radhakrishnan, Elyse E. Lower, Xiaoting Zhang, Harriet Kumar, Shugufta Khan

Publikováno v: Journal of Clinical Oncology. 32:155-155

155 Background: Overexpression of HER2/neu is associated with tamoxifen resistance in breast cancer (Osborne CK et al. J Natl Canc Inst 2003; 95:353-361). However pts may present with both estrogen receptor (ER) and HER2/neu + tumors. The benefit of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa9c8c60c9bf2ecfe63f35f7d503a483
https://doi.org/10.1200/jco.2014.32.26_suppl.155

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání